Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 7/20 | 0.78 |
| ▸ | BCAT1 | P54687 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71110 | 0.90 | TTR (0.68) | TTRBCAT1NPC1RAB9AKDM4E | |
| SCHEMBL14124833 | 0.90 | TTR (0.65) | TTRBCAT1NPC1RAB9APTGER4 | |
| SCHEMBL16714053 | 0.89 | TTR (0.84) | TTRNPC1RAB9APTGER4LMNA | |
| SCHEMBL1787556 | 0.88 | TTR (1.00) | TTRNPC1RAB9AKDM4EMAPT | |
| SCHEMBL11471734 | 0.87 | TTR (0.81) | TTRNPC1RAB9APTGER4LMNA | |
| SCHEMBL11768568 | 0.87 | TTR (0.65) | TTRBCAT1NPC1RAB9APTGER4 | |
| Hydrochloric Acid SCHEMBL11367851 | 0.86 | TTR (0.97) | TTRNPC1RAB9AKDM4EMAPT | |
| SCHEMBL15071004 | 0.86 | TTR (0.59) | TTRBCAT1NPC1RAB9ALMNA | |
| SCHEMBL14124715 | 0.86 | TTR (0.59) | TTRBCAT1NPC1RAB9ALMNA | |
| SCHEMBL6202281 | 0.86 | TTR (0.59) | TTRBCAT1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | claimed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | claimed |
| EP-2141990-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | claimed |
| US-20090076268-A1 | Facile assembly of fused benzofuro-heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| WO-2009035668-A1 | FACILE ASSEMBLY OF FUSED BENZOFURO-HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | claimed |
| WO-2008119017-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-10-02 | — | — | WO | claimed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
| JP-51118757-A | — | — | None | — | — | JP | disclosed |
| CN-117658749-B | Method for preparing aryl carboxylic acid by reacting copper compound catalyzed aryl sulfonium salt with carbon dioxide | NANKAI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-117658749-A | Method for preparing aryl carboxylic acid by reacting copper compound catalyzed aryl sulfonium salt with carbon dioxide | 南开大学 | 2024-03-08 | — | — | CN | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021170-A1 | ANTITUMOUR TETRACYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-08-10 | — | — | WO | disclosed |
| EP-0651750-A1 | TETRACYCLIC COMPOUNDS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOUR AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002483-A1 | TETRACYCLIC COMPOUNDS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOUR AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| JP-S51118757-A | PROCESS FOR PREPARATION OF DIBENZOFURAN-2,7-DICARBOXYLIC ACID | UBE IND LTD | 1976-10-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | TTR 862/4885BCAT1 1/4885NPC1 922/4885 |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD11B2 | TTR 2383/4885BCAT1 1391/4885NPC1 283/4885 |
| US-20090076268-A1 | Facile assembly of fused benzofuro-heterocycles | BICRA, DDC, DDT | TTR 4844/4885BCAT1 241/4885NPC1 4166/4885 |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | TTR 4788/4885BCAT1 1026/4885NPC1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.